Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entecavir - Bristol-Myers Squibb

Drug Profile

Entecavir - Bristol-Myers Squibb

Alternative Names: Baraclude; BMS-200475; SQ 34676

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antivirals; Cyclopentanes; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; RNA-directed DNA polymerase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B
  • Discontinued Herpesvirus infections

Most Recent Events

  • 03 Apr 2018 Phase III development is ongoing in South Korea for Hepatitis B (In children, In adolescents) (PO) (NCT01079806)
  • 03 Apr 2018 Bristol-Myers Squibb completes a phase III trial for Hepatitis B (In children, In adolescents) in USA, Argentina, Belgium, Brazil, Canada, Germany, Greece, India, Israel, South Korea, Poland, Romania, Russia, Taiwan and United Kingdom (PO, Tablet, Liquid) (NCT01079806)
  • 04 Sep 2017 Bristol-Myers Squibb completes a phase I/II trial in Hepatitis B (In children, In adolescents) in USA, United Kingdom, Argentina, Belgium, Brazil, Canada, South Korea and Taiwan (PO) (NCT00423891)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top